

Table S1 LNM rates (%) of the enrolled patients who were diagnosed with adenocarcinomas (N=1146)

Nodal station	Overall	Tumor location			Lobes of lung						8th pathological T status					8th clinical T status				
		Central	Peripheral	P	LUL	LLL	RUL	RML	RLL	P	pT1a	pT1b	pT1c	pT2 and above	P	cT1a	cT1b	cT1c	cT2 and above	P
2R/2L	3.9	8.8	3.3	0.002	–	–	2.8	4.4	7.9	0.007 ^a	0.0	2.3	2.5	11.9	<0.001	0.0	2.8	5.9	8.7	<0.001
3A/3P	2.4	0.0	4.0	0.61 ^a	0.0	0.0	0.0	0.0	10.0	0.32 ^a	0.0	0.0	0.0	6.7	>0.99 ^a	0.0	0.0	11.1	0.0	0.37 ^a
4R/4L	1.8	5.7	1.1	0.09 ^a	2.7	6.7	0.6	4.8	2.1	0.09 ^a	0.0	1.3	0.0	4.8	0.17 ^a	0.0	2.1	0.0	5.2	0.11 ^a
L5	2.5	6.8	2.0	0.08 ^a	3.7	0.0	–	–	–	0.046 ^a	0.0	2.7	0.9	5.8	0.09 ^a	1.1	2.5	2.3	5.8	0.10 ^a
L6	2.5	0.0	3.0	>0.99 ^a	2.3	3.7	0.0	0.0	0.0	0.53 ^a	0.0	1.2	3.3	6.9	0.23 ^a	0.0	1.4	0.0	17.6	0.005 ^a
L7	2.6	6.8	2.0	<0.001	1.3	2.1	0.9	4.0	5.6	<0.001 ^a	0.0	1.0	3.1	8.8	<0.001	0.7	1.1	2.9	11.3	<0.001
L8	2.1	0.0	2.4	>0.99 ^a	0.0	0.0	0.0	0.0	4.2	0.73 ^a	0.0	0.0	0.0	7.1	0.26	0.0	0.0	7.1	5.0	0.19 ^a
L9	1.6	5.7	1.0	0.04 ^a	0.0	0.9	0.0	0.0	2.9	0.45 ^a	0.0	0.4	0.9	7.3	0.001 ^a	0.0	0.7	0.0	10.2	<0.001 ^a
L10	3.1	7.2	2.6	<0.001	3.9	2.7	1.8	3.0	4.9	0.009 ^a	0.2	1.0	2.5	11.2	<0.001	1.2	1.2	5.1	10.3	<0.001
L11	2.7	5.4	2.4	0.005	1.9	1.9	2.1	3.6	5.1	0.009	0.3	1.1	2.1	10.0	<0.001	1.5	2.3	3.0	5.7	0.01
L12	3.9	10.1	3.0	<0.001	5.7	2.3	2.9	5.4	3.6	0.13 ^a	0.0	2.4	5.4	9.9	<0.001	0.3	2.9	4.9	12.9	<0.001
L13	1.9	4.6	1.6	0.050	1.9	1.6	1.4	6.3	2.1	0.40 ^a	0.0	1.0	2.1	6.4	0.001 ^a	0.0	1.3	3.2	5.3	0.01 ^a

^aFisher's exact test.**Table S2** LNM rates (%) of the enrolled patients who were diagnosed with squamous cell carcinomas (N=162)

Nodal station	Overall	Tumor location			Lobes of lung						8th Pathological T status					8th clinical T status				
		Central	Peripheral	P	LUL	LLL	RUL	RML	RLL	P	pT1a	pT1b	pT1c	pT2 and above	P	cT1a	cT1b	cT1c	cT2 and above	P
2R/2L	1.1	1.4	0.0	>0.99 ^a	–	–	1.1	0.0	1.3	>0.99 ^a	0.0	0.0	0.0	2.6	0.51 ^a	0.0	0.0	0.0	2.4	0.69 ^a
3A/3P	0	0.0	0.0	–	0.0	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–
4R/4L	0	0.0	0.0	–	0.0	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–
L5	2.6	2.1	5.0	0.44 ^a	4.5	0.0	–	–	–	0.28 ^a	0.0	0.0	0.0	5.2	0.82 ^a	0.0	0.0	0.0	5.0	0.67 ^a
L6	0	0.0	0.0	–	0.0	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–
L7	2.9	4.0	0.0	0.09 ^a	0.0	6.6	0.0	0.0	3.4	0.07 ^a	0.0	1.3	1.1	4.5	0.34 ^a	0.0	3.0	0.0	4.1	0.39 ^a
L8	0	0.0	0.0	–	0.0	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–
L9	0	0.0	0.0	–	0.0	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–
L10	4.5	5.3	2.1	0.12	3.1	7.1	3.4	14.3	2.9	0.19 ^a	0.0	6.2	1.9	5.5	0.08 ^a	0.0	3.4	7.1	3.8	0.44 ^a
L11	4.9	5.2	3.9	0.86 ^a	4.0	5.0	7.7	0.0	4.3	0.82 ^a	0.0	2.9	4.7	6.4	0.51 ^a	0.0	4.8	10.8	3.0	0.06 ^a
L12	6.7	8.1	2.9	0.25 ^a	2.6	12.3	0.0	25.0	12.0	0.002 ^a	20.0	6.3	6.6	5.8	0.66 ^a	0.0	5.6	6.5	8.3	0.93 ^a
L13	4.8	4.9	4.7	>0.99 ^a	5.3	4.8	8.3	0.0	0.0	0.89 ^a	0.0	10.5	2.7	4.8	0.57 ^a	0.0	6.7	3.4	5.6	>0.99 ^a

^aFisher's exact test.**Table S3** LNM rates (%) of the enrolled patients who were diagnosed with adenocarcinomas in central lung cancer (N=130)

Nodal station	Overall	Lobes of lung						8th Pathological T status					8th clinical T status				P
		LUL	LLL	RUL	RML	RLL	P	pT1a	pT1b	pT1c	pT2 and above	P	cT1a	cT1b	cT1c	cT2 and above	
2R/2L	8.8	–	–	3.4	8.3	22.9	0.003 ^a	0.0	8.3	0.0	11.9	0.30 ^a	0.0	9.3	8.6	8.6	>0.99 ^a
3A/3P	0.0	0.0	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–
4R/4L	5.7	7.1	20.0	0.0	0.0	12.5	0.16	0.0	0.0	0.0	7.5	>0.99 ^a	0.0	0.0	0.0	10.3	0.41 ^a
L5	6.8	10.3	0.0	–	–	–	0.18 ^a	0.0	11.1	0.0	9.1	0.60 ^a	0.0	11.1	4.8	5.0	0.68 ^a
L6	0.0	0.0	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–
L7	6.8	0.0	0.0	1.3	10.0	20.3	0.000 ^a	0.0	1.2	12.5	9.4	0.03 ^a	0.0	1.1	0.0	16.5	<0.001 ^a
L8	0.0	0.0	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–	0.0	0.0	0.0	0.0	–
L9	5.7	0.0	0.0	0.0	0.0	13.0	0.50 ^a	0.0	5.3	8.3	4.8	>0.99 ^a	0.0	4.2	0.0	10.5	0.58 ^a
L10	7.2	5.7	3.8	6.0	20.0	9.4	0.30 ^a	0.0	1.0	5.6	12.0	0.004 ^a	0.0	1.7	8.0	11.2	0.02 ^a
L11	5.4	1.4	2.9	3.5	16.7	12.0	0.02 ^a	0.0	3.4	3.3	8.3	0.42 ^a	0.0	5.2	3.1	7.2	0.61 ^a
L12	10.1	14.1	0.0	7.7	22.2	9.8	0.22 ^a	0.0	10.3	8.3	11.1	0.96 ^a	0.0	12.2	7.0	10.8	0.74 ^a
L13	4.6	0.0	7.7	0.0	0.0	9.7	0.28 ^a	0.0	5.3	0.0	7.1	0.84 ^a	0.0	5.1	0.0	10.5	0.33 ^a

^aFisher's exact test.**Table S4** Occurrence of LNM in patients with T stage

	N0 (N=1150)	N1 (N=76)	N2 (N=82)	Total
pT1a, n (%)	189 (99.0)	2 (1.0)	0	191
pT1b, n (%)	587 (93.9)	16 (2.6)	22 (3.5)	625
pT1c, n (%)	217 (87.2)	18 (7.2)	14 (5.6)	249
pT2 and above, n (%)	157 (64.6)	40 (16.5)	46 (18.9)	243